Journal of Huntington's Disease Publishes Benefits of PBT2

Journal of Huntington's Disease Publishes Benefits of PBT2 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 12/13/12 --   Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that the
Journal of Huntington's Disease has, in its December 2012 edition,
published data showing the benefits of PBT2 in Huntington Disease*.
The paper describes PBT2's ability to inhibit the development of the
symptoms and pathological features of Huntington Disease in
pre-clinical transgenic animal models.  
"PBT2 markedly reduced neurodegeneration, significantly increased
lifespan and improved motor function and coordination in an
aggressive animal model of the disease," said lead author and Head of
Research at Prana, Associate Professor Robert Cherny.  
"It is already well established that PBT2 prevents the aggregation of
the Abeta protein outside neurons, in Alzheimer's Disease. It is also
established that the mutant Huntingtin (Htt) protein aggregates
inside the neuron in Huntington Disease. There is published evidence
that the protein aggregation in both diseases is driven by the
interaction with metals. Our work has shown that PBT2 can prevent
this protein aggregation caused by interaction with metals," he
At a recent New York Academy of Sciences symposium on targeting
metals to treat neurodegenerative diseases, Professor Steven M.
Hersch of Massachusetts General Hospital and Harvard Medical School
commented that "transition metals, especially iron and copper, have
been implicated in the pathogenesis of Huntington Disease. Copper may
directly modulate the toxicity of the Htt protein while iron
accumulation in response to neurodegeneration likely potentiates the
damage to the central nervous system, making both metals potential
therapeutic targets. PBT2 is the first clinical candidate that
modulates Htt directly."  
PBT2 is being trialed in Huntington Disease patients in 20 sites
across the USA and Australia. Results are expected in the second half
of 2013. 
Key Data Points: 

--  PBT2 reduced the toxicity caused by polyQ overexpression in a
    C.elegans roundworm (transgenic model);
--  In the R6/2 transgenic mouse model of Huntington Disease, PBT2,
    significantly reduced brain striatal atrophy (40% reduction in lateral
    ventricular volume);
--  PBT2 increased median lifespan by 26%;
--  PBT2 improved motor function (Rotorod performance);
--  PBT2 reduced the incidence of the 'clasping behavior' associated with
    striatal damage;
--  PBT2 improved maintenance of body weight.

*Cherny R.A. et al, "PBT2 reduces toxicity in a C.elegans model of
polyQ aggregation and extends lifespan, reduces striatal atrophy and
improves motor performance in the R6/2 mouse model of Huntington's
disease," J Hunt Dis (2012) 1: 211-219. DOI: 10.3233/JHD-120029 
Available Online:  
About Prana Biotechnology Limited
 Prana Biotechnology was
established to commercialize research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and
listed on the Australian Securities Exchange in March 2000 and listed
on NASDAQ in September 2002. Researchers at prominent international
institutions including The University of Melbourne, The Mental Health
Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the
discovery of Prana's technology.  
For further information please visit the Company's web site at 
Forward Looking Statements 
 This press release contains
"forward-looking statements" within the meaning of section 27A of the
Securities Act of 1933 and section 21E of the Securities Exchange Act
of 1934. The Company has tried to identify such forward-looking
statements by use of such words as "expects," "intends," "hopes,"
"anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not
the exclusive means of identifying such statements. Such statements
include, but are not limited to any statements relating to the
Company's drug development program, including, but not limited to the
initiation, progress and outcomes of clinical trials of the Company's
drug development program, including, but not limited to, PBT2, and
any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those
risks and uncertainties relating to the difficulties or delays in
financing, development, testing, regulatory approval, production and
marketing of the Company's drug components, including, but not
limited to, PBT2, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds,
including, but not limited to, PBT2, that could slow or prevent
products coming to market, the uncertainty of patent protection for
the Company's intellectual property or trade secrets, including, but
not limited to, the intellectual property relating to PBT2, and other
risks detailed from time to time in the filings the Company makes
with Securities and Exchange Commission including its annual reports
on Form 20-F and its reports on Form 6-K. Such statements are based
on management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements
as a prediction of actual future results. 
Prana Biotechnology
+61 3 9349 4906 
Leslie Wolf-Creutzfeldt
T: 646-284-9472
Press spacebar to pause and continue. Press esc to stop.